Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance

0
0 / 5 (0 votos)

The Lancet Haematology

Fecha de publicación: 1 december 2018

DOI: https://doi.org/10.1016/S2352-3026(18)30181-9

Autores: Oliver Ottmann

Background: Before the advent of tyrosine kinase inhibitor (TKI) therapy, Philadelphia chromosome-positive acute lymphoblastic leukaemia had an exceptionally poor prognosis and was a clear indication for allogeneic haemopoietic stem cell transplantation (HSCT). Adding TKIs to frontline therapy improves survival, with transplantation in paediatric patients increasingly reserved for those with poor response.

Seguir leyendo